Skip to main content

Serologicals Licenses from Myriad Suite of Cancer-Risk Proteins and Antibodies

NEW YORK, Jan. 15 (GenomeWeb News) - Serologicals' Chemicon International division has licensed certain tumor suppressor and breast cancer proteins and antibodies made by Myriad Genetics, the companies said today.

 

The exclusive agreement, which enables Chemicon to use the targets only for research purposes, covers the BRCA1, BRCA2, p16, p15, and p14 proteins and antibodies. However, the agreement "excludes commercial therapeutic and diagnostic rights and rights to fields of use that Chemicon does not currently serve," the companies said.

 

BRCA1 and BRCA2 are the two well-recognized cancer-susceptibility genes expressed in breast and ovarian cancers and cell lines, while cyclin-dependent kinase inhibitors p16, p15, and p14 act as tumor suppressor genes. They are known to be frequently deleted or mutated in a wide variety of human tumors.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.